Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is a selective sinus node (If) channel inhibitor presented as an oral formulation for oral use. It reduces heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction, helping to improve symptoms and reduce cardiovascular events.

GNH USA supplies Ivabradine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes.

- Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization when added to standard heart‑failure therapy.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below the desired range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo: especially on standing. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic heart block. - Persistent visual disturbances affecting daily activities.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor heart rate: ensure resting heart rate is above 60 bpm before starting. - Avoid in severe hepatic impairment: drug clearance may be reduced. - Caution in sick‑sinus syndrome: risk of excessive bradycardia. - Do not combine with strong CYP3A4 inhibitors: may increase plasma levels. - Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Ivabradine can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations. - Other bradycardic agents (beta‑blockers, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Certain anti‑arrhythmic drugs (e.g., amiodarone): can potentiate cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Drugs affecting electrolyte balance (e.g., diuretics): monitor for arrhythmia risk.